Cat. No. 2782
Chemical Name: 1,3-Dihydro-5-[3-[4-(phenylmethyl)-1-2H-benzimidazol-2-one
Biological ActivityOrally active, subtype-selective NR1A/NR2B NMDA receptor antagonist (IC50 values are 5.3, 35000 and > 100000 nM for NR1A/2B, NR1A/2A and NR1A/2C receptor subtypes respectively). Potentiates the effect of L-DOPA in 6-OHDA-lesioned rats following oral administration.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Wright et al (2000) Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines. J.Med.Chem. 43 3408. PMID: 10978188.
Roger et al (2003) Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[11C]one, as a potent NR1A/2B subtype selective NMDA PET radiotracer. Bioorg.Med.Chem. 11 5401. PMID: 14642584.
If you know of a relevant citation for this product please let us know.
Keywords: TCS 46b, supplier, Orally, active, subtype-selective, NR1A/NR2B, antagonists, Glutamate, NMDA, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, TCS46b
Find multiple products by catalog number
New Products in this Area
Non-competitive AMPA/kainate antagonistQNZ 46
NR2C/NR2D-selective NMDA receptor non-competitive antagonist
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.